Skip to content
Wenlo
Sign in
← Markets

Natera, Inc.

Solomon Moshkevich (PRESIDENT, CLINICALDIAGNOSTICS) sells NTRA shares

4NTRAFiled Nov 4, 2026, 9:35 PM ET· Period Nov 2, 2026

AI-generated summary

PRESIDENT, CLINICALDIAGNOSTICS Solomon Moshkevich sold 3,419 shares of common stock for approximately $1,400,994 at an average price of $409.77 per share. The transactions took place on November 2, 2026, pursuant to a Rule 10b5-1 trading plan adopted on November 26, 2024. Following these sales, the insider directly held 101,323 shares.

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

Insider
Solomon Moshkevich · PRESIDENT, CLINICALDIAGNOSTICS

Rule 10b5-1 plan · adopted Nov 26, 2024

DateTransactionSharesPriceValueHeld afterOwnership
Nov 2, 2026S · open-market saleFootnotes F1−9$388.20$3,493.80104,733Direct
Nov 2, 2026S · open-market saleFootnotes F1−410$400.29$164,120.62104,323Direct
Nov 2, 2026S · open-market saleFootnotes F2, F3−200$405.26$81,051.20104,123Direct
Nov 2, 2026S · open-market saleFootnotes F2, F4−432$406.94$175,797.99103,691Direct
Nov 2, 2026S · open-market saleFootnotes F2, F5−408$408.08$166,498.31103,283Direct
Nov 2, 2026S · open-market saleFootnotes F2, F6−520$409.46$212,918.00102,763Direct
Nov 2, 2026S · open-market saleFootnotes F2, F7−120$410.71$49,285.80102,643Direct
Nov 2, 2026S · open-market saleFootnotes F2, F8−120$411.73$49,408.00102,523Direct
Nov 2, 2026S · open-market saleFootnotes F2, F9−120$412.88$49,546.00102,403Direct
Nov 2, 2026S · open-market saleFootnotes F2, F10−80$414.16$33,132.60102,323Direct
Nov 2, 2026S · open-market saleFootnotes F2, F11−760$415.52$315,794.97101,563Direct
Nov 2, 2026S · open-market saleFootnotes F2, F12−240$416.45$99,946.99101,323Direct
Footnotes
  1. F1 The sale of shares was effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs and was made pursuant to a written instruction that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act contained in the Reporting Person's Stock Unit Agreement granted on January 31, 2025.
  2. F2 The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024.
  3. F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $404.8500 to $405.8450 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $406.4150 to $407.3750 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $407.5550 to $408.4100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $409.13 to $409.94 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  7. F7 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $410.21 to $411.13 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  8. F8 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $411.4300 to $411.8850 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  9. F9 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $412.6200 to $413.0150 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  10. F10 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $413.8100 to $414.5050 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  11. F11 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $414.9450 to $415.6400 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  12. F12 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $416.18 to $416.73 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

More NTRA filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.